Author: Choi, Hyung Muk; Moon, Soo Youn; Yang, Hyung In; Kim, Kyoung Soo
Title: Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics Cord-id: 9wanvdnp Document date: 2021_2_9
ID: 9wanvdnp
Snippet: Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has become a worldwide pandemic. Symptoms range from mild fever to cough, fatigue, severe pneumonia, acute respiratory distress syndrome (ARDS), and organ failure, with a mortality rate of 2.2%. However, there are no licensed drugs or definitive treatment strategies for patients with severe COVID-19. Only antiviral or anti-inflammatory drugs are used as symptomatic treatments based on clinician experience. Basic medical researc
Document: Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has become a worldwide pandemic. Symptoms range from mild fever to cough, fatigue, severe pneumonia, acute respiratory distress syndrome (ARDS), and organ failure, with a mortality rate of 2.2%. However, there are no licensed drugs or definitive treatment strategies for patients with severe COVID-19. Only antiviral or anti-inflammatory drugs are used as symptomatic treatments based on clinician experience. Basic medical researchers are also trying to develop COVID-19 therapeutics. However, there is limited systematic information about the pathogenesis of COVID-19 symptoms that cause tissue damage or death and the mechanisms by which the virus infects and replicates in cells. Here, we introduce recent knowledge of time course changes in viral titers, delayed virus clearance, and persistent systemic inflammation in patients with severe COVID-19. Based on the concept of drug reposition, we review which antiviral or anti-inflammatory drugs can effectively treat COVID-19 patients based on progressive symptoms and the mechanisms inhibiting virus infection and replication.
Search related documents:
Co phrase search for related documents- ace angiotensin and acei ace inhibitor: 1, 2, 3, 4, 5, 6
- ace angiotensin and activate angiotensin: 1
- ace angiotensin and activation viral entry: 1
- ace angiotensin and acute ards: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- ace angiotensin and acute ards cardiac injury: 1
- ace angiotensin ii angiotensin and acute ards: 1, 2, 3, 4, 5, 6, 7, 8
- ace function and acute ards: 1, 2
- ace inhibitor and acei ace inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- ace inhibitor and acute ards: 1, 2, 3, 4
- aci acute ards cardiac injury and acute ards: 1, 2, 3
- aci acute ards cardiac injury and acute ards cardiac injury: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date